

# The Indian Pharmaceutical Industry: Expansion & Ambitions



*World Leaders in Health Industry Analysis*



## **The Indian Pharmaceutical Industry: Expansion & Ambitions**

ISBN: 978-1-85822-296-7

© Copyright 2007 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data

A catalogue record for this report is available from the British Library.

# **The Indian Pharmaceutical Industry: Expansion & Ambitions**

Published by Espicom Business Intelligence, September 2007

[www.espicom.com](http://www.espicom.com)

*This page left intentionally blank*

# Contents

<b>Foreword</b> .....	<b>1</b>
<b>Executive Summary</b> .....	<b>3</b>
<b>Indian Company Strategies</b> .....	<b>5</b>
Introduction.....	5
Indian bases.....	6
Sales revenue.....	7
The advent of the product patent regime in India .....	8
Background .....	8
The Patents (Amendments) Bill, 2005 .....	9
Mashelkar Committee Report, December 2006 .....	9
What effect has the advent of the product patent regime had on the Indian pharmaceutical industry? .....	10
Looking beyond reverse-engineering .....	10
In-licensing and custom manufacturing.....	11
Key markets now and in the future .....	11
Established and emerging generic markets.....	12
The United States.....	12
Authorised generics – threat or opportunity? .....	21
Europe.....	23
South Africa .....	29
Brazil .....	30
Biosimilars .....	36
India’s competitive advantage.....	37
Foreign acquisitions.....	38
<b>Company Profiles</b> .....	<b>43</b>
Aurobindo Pharma .....	43
Company Strategy.....	43
Manufacturing.....	44
R&D.....	45
Key Markets .....	45
Major Developments.....	46
Pharmacin acquisition .....	46
Acquisition of US facility .....	46
Milpharm: Aurobindo’s first acquisition in Europe.....	46
Products .....	46
APIs.....	47
Domestic Formulations.....	47

International Generics.....	47
<i>US and Canada</i> .....	47
<i>European Union</i> .....	51
<i>South Africa</i> .....	51
Financials .....	52
Cipla .....	53
Company Strategy .....	53
Manufacturing.....	53
R&D.....	54
Key Markets .....	54
Major Developments .....	55
Strategic Alliances & Agreements.....	55
<i>Drug development agreements with Akorn</i> .....	55
<i>Malaria agreement with DNDi</i> .....	55
<i>Akorn</i> .....	55
Divestiture of Cipla Medpro .....	56
Compulsory licensing in Malaysia.....	57
Products .....	57
APIs.....	57
Domestic Formulations.....	57
International Generics.....	59
<i>Antiretrovirals</i> .....	59
<i>US</i> .....	60
<i>Europe</i> .....	61
Financials .....	61
Dr. Reddy's.....	63
Company Strategy .....	63
Manufacturing.....	64
<i>USP's Pharmaceutical Ingredient Verification Programme</i> .....	65
R&D.....	66
<i>Cancer</i> .....	66
<i>Cardiovascular</i> .....	66
<i>Diabetes</i> .....	66
<i>Perlecan</i> .....	66
Key Markets .....	67
Major Developments .....	68
Mergers & Acquisitions.....	68
<i>betapharm</i> .....	68
<i>Roche's Mexico API facility</i> .....	68
<i>Trigenesis Therapeutics</i> .....	68

<i>BMS Laboratories and Meridian Health Care</i> .....	68
<i>American Remedies and Cheminor Drugs</i> .....	69
Joint Ventures.....	69
<i>China - Kunshan Rotam Reddy Pharmaceutical Co., Ltd.</i> .....	69
<i>South Africa - Dr. Reddy's Laboratories (Proprietary) Ltd.</i> .....	69
Agreements .....	69
<i>Dr. Reddy's appointed as Alchemia's partner for synthetic heparin</i> .....	69
<i>Dr. Reddy's and Torrent sign Russian lisinopril agreement</i> .....	70
<i>Dr. Reddy's and ClinTec Co-Development Agreement</i> .....	70
<i>Dr. Reddy's and Argenta announce R&amp;D collaboration</i> .....	70
<i>Dr. Reddy's and Rheoscience announce R&amp;D collaboration</i> .....	70
<i>Dr. Reddy's/Pharmascience sign multi-product agreement</i> .....	71
<i>Dr. Reddy's and ICICI form ANDA partnership</i> .....	71
<i>Pliva</i> .....	71
<i>Leiner Health Products</i> .....	71
Litigation.....	71
<i>Court rules in Eisai's favour over Aciphex ANDA</i> .....	71
<i>Dr. Reddy's/GSK settle Imitrex litigation</i> .....	72
<i>Merck &amp; Co challenges over finasteride ANDA</i> .....	72
<i>Novartis' terbinafine litigation against Dr. Reddy's comes to an end</i> .....	72
<i>Amlodipine</i> .....	73
Products .....	73
APIs.....	73
Domestic Formulations.....	74
International Generics.....	76
<i>US</i> .....	76
Financials .....	78
Glenmark Pharmaceuticals .....	81
Company Strategy .....	81
Manufacturing.....	82
R&D.....	82
Key Markets .....	83
Major Developments.....	84
Mergers & Acquisitions.....	84
<i>Glenmark purchases rights to CHR-1103 and CHR-1201 from Chromos</i> .....	84
<i>Medicamenta of the Czech Republic</i> .....	84
<i>Bouwer Bartlett, South Africa</i> .....	84
Agreements.....	85
<i>R&amp;D agreement with Dyax for therapeutic antibodies</i> .....	85
<i>Merck Generics</i> .....	85

<i>Royalty deal with Paul Capital Partners</i> .....	86
<i>Lehigh Valley Technologies</i> .....	86
<i>Aspen USA</i> .....	87
<i>Generics agreement with InvaGen for US market</i> .....	87
Products .....	87
APIs.....	87
Domestic Formulations.....	87
International Generics.....	88
US.....	88
Financials .....	89
Lupin .....	91
Company Strategy.....	91
Manufacturing.....	91
R&D.....	92
Key Markets .....	92
Major Developments .....	93
Agreements.....	93
<i>GSK Philippines</i> .....	93
<i>Allergan</i> .....	93
<i>Baxter</i> .....	93
<i>Watson Pharmaceuticals</i> .....	93
Products .....	93
APIs.....	94
Domestic Formulations.....	94
International Generics.....	94
US.....	94
<i>Europe</i> .....	96
Financials .....	97
Matrix Laboratories.....	99
Company Strategy .....	99
Manufacturing.....	100
R&D.....	100
Key Markets .....	100
Major Developments .....	101
Mergers & Acquisitions.....	101
<i>Mylan acquires Matrix</i> .....	101
<i>Aspen and Matrix finalise business relationship</i> .....	101
<i>Matrix gains 43% stake in Explora</i> .....	102
<i>Matrix acquires Docpharma</i> .....	102
<i>Matrix purchases finished dosage facility</i> .....	102

Agreements.....	103
<i>Clinton HIV/AIDS Initiative</i> .....	103
Products .....	103
APIs.....	103
International Generics.....	103
Financials .....	103
Nicholas Piramal .....	105
Company Strategy.....	105
Manufacturing.....	105
R&D.....	106
Key Markets .....	107
Major Developments.....	107
Mergers & Acquisitions.....	107
<i>Boots Piramal Healthcare</i> .....	107
<i>Pfizer's Morpeth facility</i> .....	107
<i>Rhodia's Inhalation Anaesthetics business</i> .....	108
<i>Canere</i> .....	108
<i>Sarabhai Piramal</i> .....	108
<i>ICI Pharmaceutical</i> .....	108
Agreements & Joint Ventures.....	108
<i>Eli Lilly</i> .....	108
<i>Napo Pharmaceuticals</i> .....	109
<i>BioSyntech</i> .....	109
<i>AstraZeneca</i> .....	109
<i>Allergan</i> .....	109
<i>Ethypharm</i> .....	109
<i>Biogen Idec</i> .....	109
<i>Chiesi Farmaceutici</i> .....	109
Products .....	110
APIs.....	110
Domestic Formulations.....	110
International Formulations .....	110
Financials .....	110
Orchid Chemicals & Pharmaceuticals.....	113
Company Strategy.....	113
Manufacturing.....	114
R&D.....	114
Key Markets .....	115
Major Developments.....	116
Agreements.....	116

<i>Actavis</i> .....	116
<i>Alpharma</i> .....	116
<i>Apotex</i> .....	116
<i>Par Pharmaceuticals</i> .....	117
Acquisitions & Joint Ventures .....	117
<i>Bexel Pharmaceuticals Inc.</i> .....	117
<i>Biotechnological Chemical Development Ltd.</i> .....	117
<i>Mano Pharmaceuticals &amp; Sali Healthcare</i> .....	117
<i>NCPC Orchid Pharmaceuticals Ltd.</i> .....	118
Products .....	118
APIs.....	118
Domestic Formulations.....	118
International Generics.....	118
<i>US</i> .....	119
<i>Canada</i> .....	120
Financials .....	120
Ranbaxy .....	123
Company Strategy .....	123
Manufacturing.....	124
R&D.....	125
Key Markets .....	126
Major Developments .....	127
Mergers & Acquisitions.....	127
<i>Ranbaxy acquires dermatology brands from Bristol-Myers Squibb</i> .....	127
<i>Ranbaxy acquires Be-Tabs for US\$71 million</i> .....	127
<i>Ranbaxy acquires GSK's Mundogen generic business in Spain</i> .....	127
<i>Ranbaxy acquires Terapia</i> .....	127
<i>Ranbaxy acquires generic product portfolio from Efarmes</i> .....	127
<i>RPG (Aventis)</i> .....	128
<i>Bayer</i> .....	128
<i>Ohm Laboratories</i> .....	128
Agreements.....	128
<i>Ranbaxy signs first biosimilars agreement</i> .....	128
<i>R&amp;D Agreement with GlaxoSmithKline</i> .....	128
<i>Ipca and Ranbaxy sign deal for US market</i> .....	129
<i>Ranbaxy signs Canadian licensing and supply agreements with Janssen-Ortho</i> .....	129
<i>Ranbaxy to market Lupin's TB brands in Africa</i> .....	129
<i>Ventiv Health</i> .....	129
<i>Merck and Thembalami</i> .....	130
<i>Atrix Laboratories</i> .....	130

<i>Mallinckrodt Baker</i> .....	130
<i>Medicines for Malaria Venture</i> .....	130
<i>Nippon Chemiphar</i> .....	130
<i>Signature Pharmaceuticals</i> .....	131
<i>Schwarz Pharma</i> .....	131
<i>Veratide</i> .....	131
<i>Wockhardt</i> .....	131
Litigation .....	131
<i>Lipitor</i> .....	131
<i>Atorvastatin in Denmark</i> .....	132
<i>Australian court upholds basic Lipitor patent</i> .....	132
<i>Dutch court upholds basic Lipitor patent but invalidates '281 patent</i> .....	132
<i>US CAFC upholds Pfizer's basic atorvastatin patent but invalidates second</i> .....	132
<i>UK Court of Appeal upholds Pfizer patent</i> .....	133
<i>Pfizer gains preliminary injunction in Finland</i> .....	133
<i>Ranbaxy gains Norwegian atorvastatin litigation success</i> .....	133
<i>UK SFO investigation; charges brought</i> .....	134
<i>UK Department of Health legal action settled</i> .....	134
Products .....	134
APIs .....	134
Domestic Formulations .....	134
International Generics .....	135
<i>US</i> .....	135
<i>Canada</i> .....	139
<i>Europe</i> .....	139
Financials .....	140
Sun Pharma .....	143
Company Strategy .....	143
Manufacturing .....	144
R&D .....	144
Key Markets .....	145
Major Developments .....	145
Mergers & Acquisitions .....	145
<i>Taro Pharmaceutical Industries</i> .....	145
<i>Able Laboratories</i> .....	146
<i>Valeant</i> .....	146
<i>Women's First Healthcare brands</i> .....	146
<i>Phlox Pharma</i> .....	146
<i>Pradeep Drug Company Ltd</i> .....	146
<i>Milmet Labs</i> .....	146

<i>MJ Pharma</i> .....	147
<i>Caraco</i> .....	147
<i>Tamil Nadu Dadha Pharma</i> .....	147
<i>Gujarat Lyka Organics</i> .....	147
Litigation.....	147
<i>Caraco gains tramadol/acetaminophen appellate court ruling</i> .....	147
Products .....	147
APIs.....	147
Domestic Formulations.....	148
International Generics.....	148
Financials .....	150
Wockhardt .....	152
Company Strategy .....	152
Manufacturing.....	153
R&D.....	153
Key Markets .....	154
Major Developments .....	154
Acquisitions.....	154
<i>Negma Laboratories</i> .....	154
<i>Pinewood Laboratories</i> .....	155
<i>CP Pharmaceuticals Ltd</i> .....	155
<i>Merind Ltd</i> .....	155
<i>Wallis Laboratory</i> .....	156
Agreements & Joint Ventures .....	156
<i>Wockhardt Mexico</i> .....	156
<i>Wockhardt South Africa</i> .....	156
<i>Wockhardt Rhein Biotech</i> .....	156
<i>Li-Taka Pharmaceuticals</i> .....	156
<i>Ranbaxy</i> .....	156
<i>Bayer</i> .....	157
Products .....	157
APIs.....	157
Domestic Formulations.....	157
International Generics.....	158
<i>US</i> .....	158
<i>Europe</i> .....	159
Financials .....	160
Zydus Cadila .....	163
Company Strategy .....	163
Manufacturing.....	163

R&D.....	164
Key Markets .....	165
Major Developments.....	165
Mergers & Acquisitions.....	165
<i>Quimica e Farmaceutica Nikkho do Brasil</i> .....	165
<i>Nippon Universal Pharmaceutical</i> .....	165
<i>Liva Healthcare</i> .....	166
<i>Alpharma France</i> .....	166
<i>Merger into Cadila Healthcare</i> .....	166
<i>Banyan Chemicals</i> .....	167
<i>German Remedies</i> .....	167
<i>Recon Healthcare</i> .....	167
Agreements & Joint Ventures.....	167
<i>Evolupharn and Aerocid</i> .....	167
<i>Bharat Serums and Vaccines</i> .....	167
<i>Venus Remedies</i> .....	168
<i>Mallinckrodt</i> .....	168
<i>Mayne Group</i> .....	168
<i>Zambon Group</i> .....	168
<i>Zydus Byk Healthcare</i> .....	169
Litigation.....	169
<i>Three Rivers sues Zydus Cadila for ribavirin patent infringement</i> .....	169
Products .....	169
APIs.....	169
Domestic Formulations.....	169
International Generics.....	169
<i>US</i> .....	169
<i>Europe</i> .....	170
Financials .....	171
<b>SOURCES .....</b>	<b>174</b>
Epicom Sources.....	174
Others.....	174

## List of Tables

Indian Company Sales, 12 months ended 31 <sup>st</sup> March 2007 .....	8
Indian Pharmaceutical Companies' US Subsidiaries .....	13
FDA ANDA Approvals, January 2005 - July 2007 .....	14
Indian Pharmaceutical Companies' EU Subsidiaries .....	25
UK Marketing Authorisations, 2006.....	27
Indian Company Registrations of Generic Medicines in Brazil, January 2007.....	32
Indian Companies' Foreign Acquisitions.....	41
Aurobindo Pharma: Manufacturing Facilities .....	45
Aurobindo Pharma: Key Subsidiaries.....	45
Aurobindo Pharma: ANDA Approvals, 2004-2007 .....	50
Cephazone Pharma: FDA ANDA Approval, 2007 .....	51
Aurobindo Pharma: Financial Results, 2003-2007.....	52
Cipla: Manufacturing Facilities.....	54
Cipla: FDA ANDA Approvals, 2007 .....	60
Cipla: Tentative FDA ANDA Approvals.....	60
Cipla: Tentative FDA NDA Approvals.....	61
Cipla: Financial Results, 2003-2007 .....	62
Dr. Reddy's: Manufacturing Facilities.....	65
Dr. Reddy's: Regional Headquarters and Key Subsidiaries .....	67
Dr. Reddy's: Key API Products by Sales, 2005-2006 .....	74
Dr. Reddy's: Top 10 Brands in India, 2005-2007 .....	75
Dr. Reddy's: FDA ANDA Approvals, 2002-2007.....	77
Dr. Reddy's: Financial Summary, 2003-2007 .....	79
Glenmark: Manufacturing Facilities.....	82
Glenmark: Key Subsidiaries .....	83
Glenmark: FDA ANDA Approvals, 2006-2007.....	88
Glenmark: Financial Results, 2003-2007 .....	89
Lupin: Manufacturing Facilities.....	92
Lupin: Leading Brands in India, 2007 .....	94
Lupin: FDA ANDA Approvals .....	96
Lupin: Tentative FDA Approvals .....	96
Lupin: Financial Results, 2003-2007 .....	97
Matrix: Manufacturing Facilities.....	100
Matrix: Tentative FDA ANDA Approvals .....	103
Matrix: Financial Results, 2003-2007 .....	104
NPIL: Manufacturing Facilities.....	106

---

NPIL: Financial Results, 2003-2007 .....	111
NPIL: Branded Formulations Revenue by Therapeutic Area, 2006-2007 (Rs. Million) .....	112
Orchid: Manufacturing Facilities.....	114
Orchid: Key Subsidiaries and Joint Ventures.....	115
Orchid: Top Ten Brands .....	118
Orchid: FDA ANDA Approvals, 2005-2007.....	120
Orchid: Financial Results, 2003-2007 .....	121
Ranbaxy: Manufacturing Facilities .....	125
Ranbaxy: Regional Headquarters & Key Subsidiaries .....	126
Ranbaxy Laboratories: FDA ANDA Approvals, 2002-2007.....	137
Ohm Laboratories: FDA ANDA Approvals, 2006-2007 .....	139
Ranbaxy: Financial Results, 2003-2006 .....	141
Ranbaxy: Formulations Sales by Country/Region, 2006 (US\$ Million) .....	141
Sun Pharma: Manufacturing Facilities.....	144
Sun Pharma: Key Subsidiaries .....	145
Sun Pharma: FDA ANDA Approvals, 2006-2007.....	149
Caraco Pharmaceutical: ANDA Approvals, 2002-2007 .....	150
Sun Pharma: Financial Results, 2003-2007 .....	151
Wockhardt Manufacturing Facilities.....	153
Wockhardt: Key Subsidiaries .....	154
Wockhardt: FDA ANDA Approvals, 2003-2007 .....	159
Wockhardt: Financial Results, 2003-2006 .....	161
Wockhardt: Sales by Region, 2006.....	161
Zydus Cadila: Manufacturing Facilities .....	164
Zydus Cadila: Key Subsidiaries .....	165
Zydus: ANDA Approvals, 2005-2007 .....	170
Zydus Cadila: Consolidated Results, 2006-2007 .....	171
Cadila Healthcare: Financial Results, 2003-2007.....	172
Zydus Cadila: Domestic Formulations Sales by Therapy Area, 2006.....	173

## List of Figures

Map: Indian Pharmaceutical Company Headquarters .....	6
Map: Manufacturing Locations in India .....	7
Map: Indian Companies in the US .....	13
Map: Indian Companies in the UK and Ireland .....	26
Map: Indian Companies in Continental Europe .....	29
Map: Indian Companies in Brazil.....	30
Map: Indian Companies in China.....	38
Cipla: Exports by Region, 2007 (%).....	62
Dr. Reddy's: Sales by Region, 2006 (%).....	79
Dr. Reddy's: Sales by Region, 2007 (%).....	80
Glenmark: Formulations Sales by Region, 2007 (%) .....	90
Lupin: Domestic & Export Sales, 2007 .....	98
Matrix: Sales by Region, 2006 (%).....	104
NPIL: Domestic Formulations Revenue by Therapeutic Area, 2007 (%) .....	112
Orchid: API Sales by Region, 2007 (%).....	121
Orchid: Formulations Sales by Region, 2007 (%) .....	122
Ranbaxy: Formulations Sales by Region, 2006 (%).....	142
Sun Pharma: Domestic & Export Sales, 2007 .....	151
Wockhardt: Sales by Region, 2006 (%) .....	162
Zydus Cadila: Sales by Region, 2007 (%) .....	172
Zydus Cadila: Domestic Formulations Sales by Therapy Area, 2006 (%).....	173